Activation of the MEK-S6 pathway in high-grade ovarian cancers. - Wikidata - awgldk - TriplyDB

Activation of the MEK-S6 pathway in high-grade ovarian cancers.

Activation of the MEK-S6 pathway in high-grade ovarian cancers.

http://www.wikidata.org/entity/Q34339010

about

Expression of the Carboxy-Terminal Portion of MUC16/CA125 Induces Transformation and Tumor Invasion A phase II evaluation of selumetinib (AZD6244, ARRY-142886), a selective MEK-1/2 inhibitor in the treatment of recurrent or persistent endometrial cancer: an NRG Oncology/Gynecologic Oncology Group study Impact of PI3K/AKT/mTOR pathway activation on the prognosis of patients with head and neck squamous cell carcinomas.A preclinical evaluation of the MEK inhibitor refametinib in HER2-positive breast cancer cell lines including those with acquired resistance to trastuzumab or lapatinib.Increased phosphorylation of ERK1/2 is associated with worse chemotherapeutic outcome and a poor prognosis in advanced lung adenocarcinoma.

P2860

Q27307193-187BF7E6-4234-4407-BB81-1B688A2D0288 Q35748507-F939BE4E-BA5B-4570-BF4D-EA8175CA237E Q37301942-DB3D6AF7-B7F4-46B3-95A2-0B4E3EB5B023 Q46780069-99BD05DC-0E73-4B7C-A6A3-BC08E0049161 Q51562158-51BFB9E4-29D3-4EB8-B9D5-CF42DDB575EE

P2860

Activation of the MEK-S6 pathway in high-grade ovarian cancers.

http://www.wikidata.org/entity/Q34339010

description

2010 nî lūn-bûn

@nan

2010 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի դեկտեմբերին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Activation of the MEK-S6 pathway in high-grade ovarian cancers.

@ast

Activation of the MEK-S6 pathway in high-grade ovarian cancers.

@en

Activation of the MEK-S6 pathway in high-grade ovarian cancers.

@nl

type

label

Activation of the MEK-S6 pathway in high-grade ovarian cancers.

@ast

Activation of the MEK-S6 pathway in high-grade ovarian cancers.

@en

Activation of the MEK-S6 pathway in high-grade ovarian cancers.

@nl

prefLabel

Activation of the MEK-S6 pathway in high-grade ovarian cancers.

@ast

Activation of the MEK-S6 pathway in high-grade ovarian cancers.

@en

Activation of the MEK-S6 pathway in high-grade ovarian cancers.

@nl

P1433

Q34339010-880A8476-6F9E-486E-9F66-0726C660848C

P1476

Q34339010-4FE12CF1-D8B1-4326-9F10-B138DF1CC9F6

P2093

Q34339010-5C2042A2-108F-47A8-BEEE-297AF5ACA25B

Q34339010-75672597-EC7E-4907-B31A-37874387F994

Q34339010-7995CE28-BDFF-4CF6-8042-B8D49D307136

Q34339010-94323EB5-CDC5-4114-BD18-B97209A5A9FC

Q34339010-9F2F59CF-3AD0-44D1-9700-551F4508A409

Q34339010-AF34EF53-ED61-40DE-9049-8F5C742341B4

Q34339010-BECE9178-8C7A-481F-8C60-25FD223A2441

Q34339010-CA92A613-9B21-4AAB-B941-27ADBBC8130A

Q34339010-E31D3DA4-5C30-48A9-BCAD-5CC68D15A9C8

Q34339010-EC7F21A8-D6FF-4799-8B8F-C4826038290E

P2860

Q34339010-07A5F1CE-B762-46B5-8428-D4FAA4B6F6EF

Q34339010-0EA8B125-D03B-4256-B20F-16D44D1913A1

Q34339010-14C60AE9-108A-4042-8229-8BD6535AD0F2

Q34339010-2084181C-48AA-48B8-8ADC-A6E18696A308

Q34339010-21FECC3B-CAAD-4E62-A74F-852874146A11

Q34339010-25338755-336E-4354-9D8C-B7FB4056F582

Q34339010-3452E60A-B015-484A-81F1-3240D2122968

Q34339010-3629973D-0EA8-4B46-A79D-9F289FABCC15

Q34339010-38B4B319-7A99-4036-87F2-723889E5ABCB

Q34339010-3E2F1D26-61DE-4DD3-8772-F91F21AD2850

P304

Q34339010-5C0E5E8C-15C8-48F1-9FC4-6CB176D18067

P31

Q34339010-FB150102-AF5E-40C8-91DA-E03324775851

P356

Q34339010-76F98AE0-DB9B-48D9-AE48-A317EB67AEAF

P433

Q34339010-FDF40369-E125-4806-9BB0-72F1AC562AB2

P478

Q34339010-0C579381-5760-467F-85BB-2CE80CD25B40

P577

Q34339010-A9108E6E-8E76-46A6-B9EE-1ADB8ADBF0BE

P698

Q34339010-9ADA6815-5A7B-4B35-BC43-598D1C79CEDD

P921

Q34339010-04ADBA5B-61A7-4AE7-84DB-2F0DEC9195D9

P932

Q34339010-41C5C078-5015-44A6-A74A-2C7A20681415

P356

PAI.0B013E3181E53E1C

P1433

Applied Immunohistochemistry & Molecular Morphology

P1476

Activation of the MEK-S6 pathway in high-grade ovarian cancers.

@en

P2093

Ann Green

http://www.w3.org/2001/XMLSchema#string

April N Allen

http://www.w3.org/2001/XMLSchema#string

Aviva P Ventura

http://www.w3.org/2001/XMLSchema#string

Beatrice S Knudsen

http://www.w3.org/2001/XMLSchema#string

Beth Karlan

http://www.w3.org/2001/XMLSchema#string

Charles Drescher

http://www.w3.org/2001/XMLSchema#string

Kathy O'Briant

http://www.w3.org/2001/XMLSchema#string

Michèl Schummer

http://www.w3.org/2001/XMLSchema#string

Muneesh Tewari

http://www.w3.org/2001/XMLSchema#string

Nicole Urban

http://www.w3.org/2001/XMLSchema#string

P2860

The mTOR/PI3K and MAPK pathways converge on eIF4B to control its phosphorylation and activity

AKT2, a putative oncogene encoding a member of a subfamily of protein-serine/threonine kinases, is amplified in human ovarian carcinomas

The RSK family of kinases: emerging roles in cellular signalling

Evidence that pp42, a major tyrosine kinase target protein, is a mitogen-activated serine/threonine protein kinase.

RDEA119/BAY 869766: a potent, selective, allosteric inhibitor of MEK1/2 for the treatment of cancer

Rapamycin-FKBP specifically blocks growth-dependent activation of and signaling by the 70 kd S6 protein kinases

Regulation of the MAP kinase cascade

4E-binding protein 1: a key molecular "funnel factor" in human cancer with clinical implications

Normal and malignant prostate epithelial cells differ in their response to hepatocyte growth factor/scatter factor

Mammalian cell size is controlled by mTOR and its downstream targets S6K1 and 4EBP1/eIF4E

P304

499-508

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1097/PAI.0B013E3181E53E1C

http://www.w3.org/2001/XMLSchema#string

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

18

http://www.w3.org/2001/XMLSchema#string

P577

2010-12-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

20661131

http://www.w3.org/2001/XMLSchema#string

P921

P932

2989426

http://www.w3.org/2001/XMLSchema#string